B
Bronislaw Pytowski
Researcher at Eli Lilly and Company
Publications - 72
Citations - 8698
Bronislaw Pytowski is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Lymphangiogenesis & Vascular endothelial growth factor C. The author has an hindex of 41, co-authored 70 publications receiving 8202 citations. Previous affiliations of Bronislaw Pytowski include Columbia University & ImClone Systems.
Papers
More filters
Journal ArticleDOI
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
Tuomas Tammela,Georgia Zarkada,Elisabet Wallgard,Aino Murtomäki,Steven Suchting,Maria Wirzenius,Marika Waltari,Mats Hellström,Tibor Schomber,Reetta Peltonen,Catarina Freitas,Antonio Duarte,Helena Isoniemi,Pirjo Laakkonen,Gerhard Christofori,Seppo Ylä-Herttuala,Masabumi Shibuya,Bronislaw Pytowski,Anne Eichmann,Christer Betsholtz,Kari Alitalo +20 more
TL;DR: It is demonstrated that VEGFR-3 is highly expressed in angiogenic sprouts, and genetic targeting or blocking of VEG FR-3 signalling with monoclonal antibodies results in decreased sprouting, vascular density, vessel branching and endothelial cell proliferation in mouse angiogenesis models, implicate VEGfr-3 as a regulator of vascular network formation.
Journal Article
Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors
Marie Prewett,James Huber,Yiwen Li,Angel Santiago,William T. O'Connor,Karen King,Jay Overholser,Andrea T. Hooper,Bronislaw Pytowski,Larry Witte,Peter Bohlen,Daniel J. Hicklin +11 more
TL;DR: The conclusion that anti-Flk-1 mAb treatment inhibits tumor growth by suppression of tumor-induced neovascularization is supported and the potential for therapeutic application of anti-VEGF receptor antibody in the treatment of angiogenesis-dependent tumors is demonstrated.
Journal ArticleDOI
Engraftment and Reconstitution of Hematopoiesis Is Dependent on VEGFR2-Mediated Regeneration of Sinusoidal Endothelial Cells
Andrea T. Hooper,Jason M. Butler,Jason M. Butler,Daniel J. Nolan,Daniel J. Nolan,Andrea Kranz,Kaoruko Iida,Mariko Kobayashi,Mariko Kobayashi,Hans-Georg Kopp,Hans-Georg Kopp,Koji Shido,Koji Shido,Isabelle Petit,Isabelle Petit,Kilangsungla Yanger,Kilangsungla Yanger,Daylon James,Daylon James,Larry Witte,Zhenping Zhu,Yan Wu,Bronislaw Pytowski,Zev Rosenwaks,Vivek Mittal,Thomas N. Sato,Shahin Rafii,Shahin Rafii +27 more
TL;DR: In this article, the authors found that VEGFR2 expression specifically demarcated a continuous network of arterioles and sinusoidal endothelial cells (SECs) within the BM.
Journal ArticleDOI
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation
Peter Baluk,Tuomas Tammela,Erin Ator,Natalya Lyubynska,Marc G. Achen,Daniel J. Hicklin,Michael Jeltsch,Tatiana V. Petrova,Bronislaw Pytowski,Steven A. Stacker,Seppo Ylä-Herttuala,David A. Jackson,Kari Alitalo,Donald M. McDonald +13 more
TL;DR: It is suggested that when lymphangiogenesis is impaired, airway inflammation may lead to bronchial lymphedema and exaggerated airflow obstruction, and Correction of defective lymphang iogenesis may benefit the treatment of asthma and other inflammatory airway diseases.
Journal ArticleDOI
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
Larry Witte,Daniel J. Hicklin,Zhenping Zhu,Bronislaw Pytowski,Helen Kotanides,Patricia Rockwell,Peter Bohlen +6 more
TL;DR: Although these antibodies cannot be tested for in vivo efficacy in standard murine tumor models because of lack of species cross-reactivity, the similarity of their in vitro properties with those of DC101 suggests that they may be effective in blocking KDR function in vivo.